Study to Evaluate the Clinical Outcomes in Adults With Covid-19 Who Have Been Treated With Remdesivir. (909REM)

NEAT ID Foundation

Status

Completed

Conditions

Covid19

Treatments

Drug: Remdesivir

Study type

Observational

Funder types

Other

Industry

Identifiers

NCT04847622

NEAT ID 909REM

Details and patient eligibility

About

This is a multi-centre, multi-country retrospective cohort study. At least 450COVID-19 cases from up to 20 participating study sites who meet all eligibility criteria will be included in the analysis. Deidentified data will be extracted from electronic medical record (EMR) databases, clinical registries, case series or additional sources from participating sites and countries, and then entered into a structured e-CRF system. addition, each site/country will be surveyed to determine the local standard of care therapy for COVID-19 infection and to determine if standard protocols were/are in place for the use of Remdesivir and if/how the protocols changed over time.

Enrollment

451 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

All Adult participants with COVID-19 confirmed by PCR who meet the following criteria:

Hospitalised after August 31st,2020
Receivedat least one dose of Remdesivir(RDV)at anytime during hospitalisation

Exclusion criteria

Received Remdesivir as part of a clinical trial, compassionate use or expanded access program
Received Remdesivir prior to this admission at any other health facility than the research sites and whose health records are available.